Media release

DKSH has signed an agreement to acquire Molecular Diagnostics Korea Inc. (“MDxK”), a well- established player in the South-Korean life-science space. With this transaction, DKSH Technology further extends its scientific solutions business in line with the Business Unit’s strategy to solidify its position as a leading scientific solutions provider in Asia and Beyond.

Zurich, Switzerland, March 26, 2025 – DKSH has announced today that it signed an agreement to acquire MDxK, a well-established South Korean provider of advanced scientific solutions. MDxK specializes in providing state-of-the-art solutions for molecular diagnostics, cellular analysis, structural biology, and biobanking. The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market, further complementing its scientific workflow solutions and solidifying its position in the life science sector in South Korea.

MDxK was established in 2007 and is based in Seoul, South Korea. The company builds on trusted relationships with renowned clients from the global life science industry. With a strong focus on molecular diagnostics and research, MDxK serves a wide range of customers, including hospitals, research institutes, laboratories, universities, pharma and food & beverage companies. MDxK employs around 25 people and generates annual net sales of ca. CHF 10 million¹ at good profitability.  

Hanno Elbraechter, Head Business Unit Technology at DKSH, said: “MDxK is a successful, deeply rooted scientific solutions provider that complements our offering very well. Based on trends like rising health needs and the growing emphasis on research and development, we expect demand for advanced scientific solutions in South Korea to significantly increase in the coming years. We are excited to collectively leverage MDxK’s existing business and to benefit from the synergies created by this step.”

Sungbo Shim, Owner and Managing Director of MDxK, commented: “We are delighted to see our company join DKSH, as this step represents another milestone in our nearly 20-year legacy and is part of our strategic leadership transition. We are confident our longstanding business partners, as well as our valued employees, will benefit from this step. We look forward to further growing our business, as we benefit from DKSH’s existing sales channels and networks across the market.”

The closing of the transaction is expected during the second quarter of 2025 and is subject to certain conditions.

¹ Exchange rate 1 Swiss Franc / 1’600 KRW

About DKSH 
For 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services, following its purpose of enriching people’s lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 28,060 specialists, generating net sales of CHF 11.1 billion in 2024. DKSH Business Unit Technology offers complete solutions for specialized scientific and industrial applications. With around 1,820 specialists, the Business Unit generated net sales of CHF 549 million in 2024. www.dksh.com/tec 

For more information please contact:

DKSH Holding Ltd.

Till Leisner
Head, Group Investor & Media Relations
Phone +41 44 386 7315
till.leisner@dksh.com

Melanie Grüter
Manager Group Media Relations
Phone +41 44 386 7211
melanie.grueter@dksh.com